{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"16"}],"units":"Participants"}],"groups":[{"description":"Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)","id":"BG000","title":"Part A (Dose-escalation) 60 mg"},{"description":"Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)","id":"BG001","title":"Part A (Dose-escalation) 90 mg"},{"description":"Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)","id":"BG002","title":"Part A (Dose-escalation) 120 mg"},{"description":"Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)","id":"BG003","title":"Part A (Dose-escalation) 190 mg"},{"description":"Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)","id":"BG004","title":"Part A (Dose-escalation) 240 mg"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG005","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG005","value":"9"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG005","value":"7"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG005","value":"7"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG005","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG005","value":"5"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG005","value":"11"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG005","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG005","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG005","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG005","value":"10"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG005","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG005","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG005","value":"16"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Relapsed and/or refractory TP53 WT Multiple Myeloma subjects with 1-3 lines of prior therapy."}